Fusion IP plc (AIM: FIP), the university IP commercialisation company that turns world class research into

business, is pleased to announce that Certara LP (“Certara”), a leading provider of drug discovery and

development software and scientific consulting services, has agreed to acquire Fusion?s portfolio company,

Simcyp Limited (“Simcyp”), for $32M.

Simcyp is a leading research-based company providing a modeling and simulation platform for predicting the fate

of drugs in virtual populations, including pediatric populations. The transaction moves Simcyp into the Certara

portfolio and further supports Certara?s emphasis on supporting translational science initiatives. The transaction

is conditional only upon the completion of the drawdown of Certara?s acquisition funding. It is anticipated that this

transaction will complete on 29 February 2012.

Fusion will receive approximately $6.4M in cash from the sale of its 20% shareholding in Simcyp, of which

approximately 14% is being held in escrow for a period, as security for certain warranty and indemnity cover. The

majority of the cash will be used to invest in a number of Fusion?s existing portfolio companies and for the

creation of new portfolio companies from its exclusive university partnerships, in line with its business model.

In the financial year ended July 2011, Simcyp made £1.9M post-tax profit.

David Baynes, CEO of Fusion said:

“We are delighted to announce our first significant exit from our growing portfolio of companies. Simcyp is a

world-class software company and the 200 fold return we have made on our investment amply demonstrates the

excellence of our university pipeline agreements and the value that can be extracted from these exclusive

relationships.”

Doug Liversidge CBE, Chairman of Fusion said:

“We would like to take this opportunity to thank the management and staff of Simcyp, who have built this

excellent company since our first involvement in 2005. During this time, they increased profits and turnover in

every year of our association with them and we wish them and the newly combined company every success for

the future.“

About Fusion IP

Fusion IP plc (Fusion) was established in 2002 to commercialise university-generated intellectual property. It has

long-term exclusive agreements with two of the UK?s leading research-intensive universities, the University of

Sheffield and Cardiff University, giving it exclusive access to all the IP generated by their research departments.

These exclusive agreements enable Fusion to identify world class IP and turn it into a commercial opportunity,

either through the creation of a start-up company or a license.

Fusion currently owns shareholdings is over 20 portfolio companies, including significant shareholdings in Seren,

Simcyp, Magnomatics, Phase Focus, MedaPhor, Asalus and Diurnal

Fusion has a Co-Investment Agreement with IP Group plc (“IP Group”), in which IP Group has the right to acquire

for cash, 20% of Fusion?s equity in any new portfolio company. As Fusion normally owns 60% of any new

portfolio company at start-up, IP Group?s shareholding would normally equate to a 12% stake in the new portfolio

company.

Fusion IP also has a Memorandum of Understanding with Finance Wales, the provider of commercial funding to

Wales-based SMEs, which outlines a strategy of co-investment in opportunities arising from the Cardiff

Agreement.

On 8 November 2011 Fusion announced that it had raised approximately GBP5 million through a fundraising with

existing and new institutional investors. As a result of this IP Group holds an interest in approximately 26% of

Fusion.

For more information visit www.fusionip.co.uk

About Simcyp

Simcyp provides platforms for modelling and simulation of drug absorption, distribution, metabolism and

excretion (ADME) in virtual human populations and virtual laboratory animals. The company?s flagship product

the „Simcyp Population-based ADME Simulator? is used by the world?s top pharmaceutical companies (including

Pfizer, Johnson & Johnson and AstraZeneca) and is recognised as the industry?s most sophisticated platform for

the simulation of drug-drug interactions. Simcyp recently released a rat simulator, „Simcyp Rat?, which can help

reduce, refine and replace the use of laboratory animals in drug development.

Simcyp also runs educational workshops, provides consultancy services and supports academic and drug

regulatory research through the provision of not-for-profit Simulator licenses to over sixty associate institutions.

For further information please visit www.simcyp.com

About Certara

Certara™ is dedicated to improving human health through a broad spectrum of software products and services,

from molecular discovery through clinical development, with special focus on supporting translational approaches

to drug development. Certara unites Tripos® (www.tripos.com) and Pharsight® Corporation

(www.pharsight.com). Tripos provides innovative scientific software solutions and services enabling life science

researchers to improve the efficiency of molecular discovery. Pharsight provides software and consulting

services to improve productivity and decision-making in preclinical and clinical drug development.

About Pharsight

Pharsight®, a Certara™ company, is market-leading provider of software products and scientific consulting

services to help pharmaceutical and biotechnology companies improve their drug development process,

regulatory compliance and strategic decision-making. Established in 1995, the Pharsight helps customers reduce

the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of

pharmaceutical products. Pharsight leverages expertise in its software tools and in the disciplines of

pharmacology, drug and disease modeling, human genetics, biostatistics, strategic decision-making, and regulatory strategy.

About Tripos

Tripos®, a Certara™ Company, is a global leader in innovative scientific software products and services enabling

life science researchers to improve the efficiency of molecular discovery. Established in 1979, Tripos helps a

broad range of companies and research facilities accelerate the identification and optimization of new

compounds that have the potential to become marketed drugs, foods, flavorings and fragrances.